Novartis subsidiary Sandoz's antibiotics efforts bear fruit during pandemic

Sandoz stands out from other pharmaceutical companies, as it produces both the active ingredients for antibiotics and the finished product. This is a strategy that served the company well during the pandemic, says Chief Business Officer Carol Lynch.

Photo: Sandoz / PR

The pandemic has been a blessing and a curse for Sandoz's antibiotics business.

While the demand for antibiotics has generally fallen during the pandemic due to the drastic reduction in the number of surgical procedures, which also affected Sandoz's sales figures, it also caused challenges for the global supply chain, which has helped the generics manufacturer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs